Compare DexCom, Inc. (DXCM) vs Impinj Inc (PI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Impinj Inc — how do they compare? DexCom, Inc. trades at $84.38 (market cap $31.86B), while Impinj Inc trades at $186 (market cap $5.60B). The key difference: DexCom, Inc. is far larger — about 5.7× Impinj Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, Impinj Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Impinj Inc for 22 Days on average.
| DXCM | PI | |
|---|---|---|
Market Cap | $31.86B | $5.60B |
Volume | 3,607,070 | 9,929 |
Sector | Health | Technology |
52-Week High | $92.34 | $241.91 |
52-Week Low | $54.84 | $91.34 |
Typical Hold Time | 62 Days | 22 Days |
Enterprise Value | $31.32B | $5.73B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal but strong fundamentals. Revenue grew to $4.66B in 2025, with net income of $836.3M and a 17.93% margin. The stock has a P/E of 33.32 and P/S of 6.74. Recent news highlights growth in CGM adoption for Type 2 diabetes. Analyst consensus is bullish with an average price target of $95.07, supported by 42 buy ratings.
Outlook remains positive due to earnings beats and market expansion, but risks include competition and reimbursement challenges. The stock offers growth potential, yet investors should monitor execution against high valuations and technical resistance near $85.
Impinj (PI) trades at $191.04, up 3.81% with strong technical momentum and bullish moving average signals. The company shows revenue growth with Q2 2026 earnings beating estimates, though profitability remains challenged with negative net margins. Analyst consensus is strongly bullish with 16 buy ratings and a $178.83 price target, while recent news highlights the company's positioning in RFID technology and upcoming Q3 earnings.
The stock presents growth potential from expanding RFID adoption but faces risks from persistent unprofitability and high valuation multiples. Current technical strength and institutional interest support near-term upside, though investors should monitor Q3 earnings results and margin improvement for sustained momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Impinj Inc
Impinj, Inc. is a leading provider of RAIN RFID (radio-frequency identification) solutions. The company's platform includes endpoints (tag chips), connectivity devices (readers and gateways), and software, enabling businesses to wirelessly identify, locate, and authenticate everyday items. Impinj's technology is crucial for applications in retail, supply chain management, healthcare, and logistics, helping businesses to automate inventory, track assets, and improve operational efficiency.
Read more on PI →
